TAMPA, Fla. -- The National Cancer Institute recently awarded $7.2 million for the competitive renewal of the Southeast Phase 2 Consortium (SEP2C), led by Moffitt Cancer Center's Daniel Sullivan, M.D., executive vice president and associate center director for Clinical Investigations. The renewal is through September 2016.
The SEP2C enrolls patients to phase II clinical trials and some phase I trials across six member sites. Moffitt is the lead site for the large contract that is awarded through the NCI's N01 research and development contract mechanism. The first year is projected to provide nearly $1.5 million.
The other member sites are UNC Lineberger Comprehensive Cancer; Vanderbilt-Ingram Cancer Center; Winship Cancer Institute of Emory University; VCU Massey Cancer Center; and the Cancer Institute of New Jersey.
Patient accrual at Moffitt will be focused on the following cancers: acute myeloid leukemia, breast, colorectal, lung, myelodysplastic syndrome, melanoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian and sarcoma, as well as on immunotherapy and novel phase I trials. The consortium provides full management of the clinical trials including initiation, assessing eligibility, recruitment, evaluation of toxicity and response, auditing, follow-up, and analysis of results.
|Contact: Ferdie DeVega|
H. Lee Moffitt Cancer Center & Research Institute